NCI-H1975 adenocarcinoma cells, which harbor both the L858R substitution associated with sensitivity to Gefitinib and the “gatekeeper” T790M missense mutation linked with resistance to EGFR-TKIs, are refractory to Gefitinib (IC50> 20 μM). Here, EGFR is linked to adenocarcinoma.